Global Genes: ORPHAN Cures Act Removed from Senate Budget Reconciliation Bill

While industry groups and rare disease patient advocacy organizations, such as the Biotechnology Innovation Organization and National Organization for Rare Disorders, support passage of the ORPHAN Cures Act, other groups, such as Public Citizen, AARP, and Patients for Affordable Drugs Now, have opposed it.

“This decision helps protect the popular and effective Medicare Drug Price Negotiation Program and its promise of lower prescription drug prices for millions of Americans on Medicare,” said Merith Basey, executive director of Patients for Affordable Drugs Now. “We remain vigilant against any effort to revive this harmful proposal, or anything like it, and will continue fighting to ensure every patient can get the medications they need at prices they can afford.”